By Shannon Willits, NPCP, FAFS
Obesity rates across Southwest Florida mirror a troubling national pattern. Nearly four in ten American adults carry a clinical obesity diagnosis, and a significant portion live alongside at least one related chronic condition — type 2 diabetes, hypertension, metabolic syndrome, or cardiovascular disease. For decades, managing these overlapping conditions meant navigating a complicated landscape of medications, dietary counseling, and lifestyle modification, often with results that were modest and short-lived. That landscape has shifted considerably, thanks to a class of medications known as GLP-1 receptor agonists.
Names like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have become part of everyday conversation. But the full clinical picture of what these medications do — and the equally important role that structured movement must play alongside them — is one that many patients are only beginning to understand.
The Metabolic Environment These Medications Target
To appreciate why GLP-1 medications have generated such clinical enthusiasm, it helps to understand what they are designed to address. Obesity is not simply a matter of excess weight — it drives chronic, low-grade systemic inflammation. Inflammation plays a central role in insulin resistance, which underpins type 2 diabetes, metabolic syndrome, and a cascade of downstream complications, including cardiovascular disease and fatty liver disease.
Insulin resistance creates a self-reinforcing cycle: visceral fat — the kind stored around the organs — secretes pro-inflammatory signals that further impair blood glucose regulation. Left unaddressed, this accelerates arterial damage, stresses the kidneys, and elevates the risk of major cardiac events. For many patients in this cycle, lifestyle modification alone rarely breaks it quickly enough to prevent end-organ consequences.
What GLP-1 Agonists Actually Do
Glucagon-like peptide-1 (GLP-1) is a naturally occurring gut hormone released in response to eating. It stimulates insulin secretion relative to blood glucose levels, suppresses glucagon release, and signals the brain toward satiety. In people with metabolic dysfunction, this system is often blunted. GLP-1 receptor agonists pharmacologically amplify and extend these effects.
The benefits reach well beyond weight loss. Research published in Cell Reports Medicine found that GLP-1 medications improve outcomes across multiple chronic conditions — cardiovascular disease, chronic kidney disease, metabolic liver disease, and sleep apnea — through anti-inflammatory and metabolic pathways that are, in some cases, at least partially independent of the degree of weight loss achieved. These agents bind to receptors found not only in the pancreas, but in cardiomyocytes, vascular endothelial cells, the kidneys, and the central nervous system, producing a broadly systemic effect that targets root-level inflammation.
The Muscle Problem: Where the Conversation Must Not Stop
This is where prescriptions alone fall critically short — and where movement becomes non-negotiable. As effective as GLP-1 medications are at driving fat loss, they do not discriminate perfectly between fat and lean tissue. When caloric intake drops substantially, as it typically does with appetite suppression, the body will trim lean mass alongside adipose tissue unless given a clear physiological reason not to. Research analyzing data from more than 800,000 individuals confirmed that while fat mass loss significantly exceeded muscle loss, the reduction in lean tissue is real — with roughly one-quarter of total weight lost coming from lean mass in some patient populations.
This matters far beyond appearance. Skeletal muscle is the body’s primary site of glucose uptake and a major regulator of resting metabolism. Meaningful muscle loss can reduce insulin sensitivity, slow metabolic rate, and — particularly in adults over 50 — accelerate the onset of sarcopenic obesity, a condition where low muscle mass coexists with high body fat. Sarcopenic obesity carries independent cardiovascular and functional risks that are considerably harder to reverse than prevent.
The Pilates Principle: Control, Load, and Intentional Resistance
This is precisely where Pilates methodology enters the conversation. Joseph Pilates built his system on a foundational principle that medicine is now quantifying: the body performs optimally when deep stabilizing muscles are recruited first, movement is controlled through its full range, and resistance is applied with intention rather than momentum. For patients on GLP-1 therapy, this translates directly.
The Reformer, the Cadillac, and resistance-based mat work provide the mechanical loading stimulus that tells the body to protect lean tissue during caloric deficit. The spring-based resistance system inherent to classical Pilates apparatus allows progressive overload without the compressive joint forces that often make conventional weight training inaccessible to deconditioned or post-injury populations — exactly the population most likely to be managing obesity and metabolic disease. Pilates-based training also prioritizes the posterior chain and deep core musculature, both of which are disproportionately weakened in individuals with chronic metabolic conditions and sedentary histories.
Research supports this integration. A 2022 meta-analysis found that resistance training during weight loss helped individuals preserve—or even increase—lean mass while simultaneously reducing fat mass. Additional studies have demonstrated that patients who maintained a structured exercise program during GLP-1 treatment retained significantly more of their results after discontinuing medication, a critical consideration for long-term weight management and metabolic health.
As promising as GLP-1 medications have proven to be, the ultimate goal is not simply weight loss. The goal is preserving the strength, mobility, metabolic health, and independence that allow people to live well for decades to come. Lower numbers on a scale may improve health risks, but maintaining muscle mass is what allows individuals to continue climbing stairs, carrying groceries, playing with grandchildren, recovering from illness, and remaining active as they age.
The most successful outcomes occur when medication and movement are viewed as partners rather than competitors. GLP-1 therapy can help quiet the inflammatory and metabolic processes that make weight loss difficult. Pilates provides the strength, stability, and functional movement necessary to build a healthier body during that process. Together, they create an approach that addresses not only how much weight is lost, but also the quality of the life that follows.
Shannon Willits, Master Pilates Educator
Shannon Willits is a Master Pilates Educator with more than 25 years of experience in functional movement, rehabilitation-informed training, and athletic performance. As the owner of seven growing Club Pilates studios in Lee County, Florida, she has become one of the region’s leading voices in Pilates education, mentoring and certifying aspiring instructors through comprehensive training programs rooted in movement science.
Shannon is STOTT Pilates certified, a Fellow of Applied Functional Science (FAFS), a Functional Golf Specialist, and a certified Gyrotonic® instructor. She is also an approved NPCP CEC Provider and the creator of the Pilates for Rotational Sports workshop, which blends performance training, injury prevention, and functional movement education for both athletes and instructors.